Invited Paper

Adjuvant Treatment in Non-Small Cell Lung Cancer


  • Mustafa Gürbüz
  • Yüksel Ürün

Received Date: 12.07.2018 Accepted Date: 09.11.2018 J Ankara Univ Fac Med 2018;71(3):112-117

Lung cancer occurred in approximately 1,8 million patients and caused an estimated 1,6 million deaths in 2012, worldwide. NSCLC constitutes approximately 85% of all lung cancers. Patients with early-stage NSCLC are surgically treated for curative goals. However, many patients are at risk of recurrence despite complete resection. This suggests that a large proportion of patients have the micrometastatic disease even at the early course of the disease. In this review, we aimed to evaluate the results of adjuvant chemotherapy, targeted therapy and immunotherapy studies to improve survival in NSCLC.

Keywords: Non-Small Cell Lung Cancer, Adjuvant Chemotherapy, Targeted Therapy, Immunotherapy

Full Text (Turkish)